

# ASCO 2018 Annual Meeting

Delivering Discoveries: Expanding the Reach of Precision Medicine

McCormick Place, Chicago, IL, June 1–5, 2018

Oral Presentations			
Authors	Title	Abstract #	Date
Aditya Bardia, Jennifer Robinson Diamond, Linda T. Vahdat, Sara M. Tolaney, <b>Joyce O'Shaughnessy</b> , Rebecca L. Moroosse, Ingrid A. Mayer, Vandana Gupta Abramson, Dejan Juric, Robert M. Sharkey, Sarah A. Washkowitz, William A. Wegener, David M. Goldenberg, Kevin Kalinsky.	Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2-metastatic breast cancer (mBC).	USOR Study # 16023 Abstract # 1004	Sunday June 3
Arlene O. Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A Huddart, Earle Frederick Burgess, <b>Mark T. Fleming</b> , Arash Rezazadeh, Begona Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T. Tagawa, Anne OHagan, Anjali Narayan Avadhani, Bob Zhong, Peter De Porre, Yohann Lorient.	First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).	USOR Study # 17165 Abstract # 4503	Sunday June 3
James L. Gulley, Michael Borre, <b>Nicholas J. Vogelzang</b> , Siobhan Ng, Neeraj Agarwal, Chris C. Parker, David William Pook, Per Rathenborg, Thomas W. Flaig, Joan Carles, Neal D. Shore, Liddy Chen, Christopher Ryan Heery, Winald R. Gerritsen, Frank Priou, Philip W. Kantoff.	Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.	USOR Study # 10223 Abstract # 5006	Monday June 4
Geoffrey R. Oxnard, Tara Maddala, Earl Hubbell, Alex Aravanis, Nan Zhang, Oliver Venn, Anton Valouev, Ling Shen, Shilpen Patel, Arash Jamshidi, Karthik Jagadeesh, Samuel Gross, Darya Filippova, John F. Beausang, Minetta C. Liu, <b>Donald A. Richards</b> , Sylvia Plevritis, Richard Thomas Williams, Anne-Renee Hartman, Charles Swanton.	Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study.	USOR Study # 16140 Abstract # LBA8501	Monday June 4
Charles Swanton, Oliver Venn, Alex Aravanis, Earl Hubbell, Tara Maddala, John F. Beausang, Darya Filippova, Samuel Gross, Arash Jamshidi, Ling Shen, Anton Valouev, Nan Zhang, Kelly L Bolton, Timothy Joseph Yeatman, <b>Michael Seiden</b> , Geoffrey R. Oxnard, Minetta C. Liu, Richard Thomas Williams, Anne-Renee Hartman, Jose Baselga.	Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study.	USOR Study # 16140 Abstract # 12003	Tuesday June 5

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

Poster Discussions			
Authors	Title	Abstract #	Date
Matthew H. Taylor, Drew W. Rasco, Marcia S. Brose, <b>Nicholas J. Vogelzang</b> , Stephen Lane Richey, Allen Lee Cohn, <b>Donald A. Richards</b> , Daniel E. Stepan, Corina E. Dutcus, Matthew Guo, Robert Charles Shumaker, Emmett V. Schmidt, Lori J. Wirth.	A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.	USOR Study # 15180 Abstract # 6016	Friday June 2
<b>David Andorsky</b> , Morton Coleman, Abdurraheem Yacoub, <b>Jason M. Melear, Heather Dawn Brooks, Suzanne R. Fanning, Kathryn S. Kolibaba</b> , Frederick Lansigan, Chris Reynolds, Jiahui Li, Dongfang Liu, Mary Llorente, Justin L. Ricker, <b>Jeff Porter Sharman</b> .	Response rate to lenalidomide plus rituximab (R2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.	USOR Study # 13064 Abstract # 7516	Monday June 4
Paul M. Barr, Stephen Douglas Smith, Mark J. Roschewski, Susan Mary O'Brien, <b>Jeff Porter Sharman, Jason M. Melear</b> , Ahmed M. Hamdy, Raquel Izumi, J. Greg Slatter, Nataliya Chernyukhin, Elena Bibikova, Ming Yin, Tianling Chen, Stephen Edward Forbes Spurgeon.	Acalabrutinib combined with PI3K $\delta$ inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.	USOR Study # 14163 Abstract # 75189	Monday June 4
Saad Zafar Usmani, Fredrik Schjesvold, Albert Oriol Rocafiguera, Lionel Karlin, <b>Robert M. Rifkin, Habte Aragaw Yimer</b> , Richard LeBlanc, Naoki Takezako, Robert Donald McCroskey, Kenshi Suzuki, Michele Cavo, Thierry Facon, Sundar Jagannath, Sagar Lonial, Razi Ghori, Mohammed Z.H. Farooqui, Jason Liao, Patricia Marinello, Jesus San-Miguel.	A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.	USOR Study # 15137 Abstract # 8010	Monday June 4
Eric A. Klein, Earl Hubbell, Tara Maddala, Alex Aravanis, John F. Beausang, Darya Filippova, Samuel Gross, Arash Jamshidi, Kathryn Kurtzman, Ling Shen, Anton Valouev, Oliver Venn, Nan Zhang, <b>David A. Smith</b> , Timothy Joseph Yeatman, Robert Tibshirani, Richard Thomas Williams, Anne-Renee Hartman, <b>Michael Seiden</b> , Minetta C. Liu.	Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.	USOR Study # 16140 Abstract # 12021	Monday June 4
Daniel J. George, Elisabeth I. Heath, A. Oliver Sartor, Guru Sonpavde, William R. Berry, Patrick Healy, Carolyn Winters, Colleen Riggan, Monika Anand, Julie Kephart, Matthew I. Milowsky, <b>Mark T. Fleming</b> , K. C. Balaji, Tian Zhang, Rhonda L. Bitting, Michael Roger Harrison, Megan Ann McNamara, Jennifer A. Freedman, Susan Halabi, Andrew J. Armstrong, Deborah Bruner.	Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).	Abstract # LBA5009	Monday June 4

Poster Presentations			
Authors	Title	Abstract #	Date
Bent Ejlersen, Carlos H. Barrios, Erhan Gokmen, <b>Nicholas Robert</b> , Noelia Martinez, John S. Link, Serafin Morales, Manuel Ruiz Borrego, Manish Bhandari, Yoshiaki Rai, Adam Luczak, Takashi Fujita, Alvin Wong, Bin Yao, Miguel Martin.	Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early stage HER2+ hormone receptor-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.	USOR Study # 8201 Abstract # 549	Friday June 2
Andrew David Seidman, Lee Steven Schwartzberg, Vinay K. Gudena, Peter Rubin, Stew Kroll, Joseph P. O'Connell, Kevin Tang, <b>Joyce O'Shaughnessy</b> .	Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.	USOR Study # 11221 Abstract # 1042	Friday June 2

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

Poster Presentations			
Authors	Title	Abstract #	Date
Wolfgang Eiermann, Hope S. Rugo, <b>Sami Diab</b> , Johannes Ettl, Sara A. Hurvitz, Anthony Goncalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A. Mina, Miguel Martin, Henri Hubert Roche, Young-Hyuck Im, Denka Markova, Iulia Cristina Tudor, <b>Joanne Lorraine Blum</b> , Alison L. Hannah, Jennifer Keating Litton.	Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).	USOR Study # 13111 Abstract # 1070	Friday June 2
Hope S. Rugo, Johannes Ettl, Natasha E. Woodward, Sara A. Hurvitz, Anthony Goncalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Kurtzshalmi, Lida A. Mina, Miguel Martin, Henri Hubert Roche, Young-Hyuck Im, Denka Markova, Iulia Cristina Tudor, Wolfgang Eiermann, <b>Joanne Lorraine Blum</b> , Alison L. Hannah, Jennifer Keating Litton.	EMBRACA: Efficacy outcomes in clinically relevant subgroups comparing talazoparib (TALA), an oral poly ADP ribose polymerase (PARP) inhibitor, to physician's choice of therapy (PCT) in patients with advanced breast cancer and a germline BRCA mutation.	USOR Study # 13111 Abstract # 1069	Friday June 2
Minetta C. Liu, Tara Maddala, Alex Aravanis, Earl Hubbell, John F. Beausang, Darya Filippova, Samuel Gross, Arash Jamshidi, Kathryn Kurtzman, Ling Shen, Anton Valouev, Oliver Venn, Nan Zhang, <b>David A. Smith</b> , Fergus Couch, Christina Curtis, Richard Thomas Williams, Eric A. Klein, Anne-Renee Hartman, Jose Baselga.	Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.	USOR Study # 16140 Abstract # 536	Friday June 2
Peter Schmid, Javier Cortes, Jonas C. S. Bergh, Lajos Pusztai, Carsten Denkert, Sunil Verma, Heather L. McArthur, Sherko Kummel, Yu Ding, Vassiliki Karantz, Thao Dang, Rebecca Alexandra Dent.	KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).	USOR Study # 16208 Abstract # TPS602	Friday June 2
Toni K. Choueiri, David I. Quinn, Tian Zhang, Howard Gurney, <b>Gurjyot K. Doshi</b> , Patrick Wayne Cobb, Francis Parnis, Jae-Lyun Lee, Se Hoon Park, Andrey Semenov, Wayne Yen-Hwa Chang, Shuyan M. Wan, Christian Heinrich Poehlein, Thomas Powles.	KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.	USOR Study # 16251 Abstract # TPS4599	Friday June 2
<b>Joyce O'Shaughnessy</b> , Martine J. Piccart-Gebhart, Lee Steven Schwartzberg, Javier Cortes, Nadia Harbeck, Seock-Ah Im, Hope S. Rugo, Michael Untch, Denise A. Yardley, Igor Bondarenko, Stephen Chan, Veronique Dieras, Luca Gianni, Mark D. Pegram, Stew Kroll, Joseph P. O'Connell, Jeffrey L. Vacirca, Thomas Wei, Kevin Tang, Andrew David Seidman.	Contessa: A multinational, multicenter, randomized, phase 3 registration study of tsetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).	USOR Study # 17009 Abstract # TPS1106	Friday June 2
Nieves Martinez Chanza, Dominick Bossé, Mehmet Asim Bilen, Daniel M. Geynisman, Archana Balakrishnan, Rohit K. Jain, I. Alex Bowman, Yousef Zakharia, Vivek Narayan, Benoit Beuselinck, Neeraj Agarwal, Rana R. McKay, Joann Hsu, Sumit Shah, Abhishek Tripathi, Elaine Tat Lam, Tracy Lynn Rose, Benedito A. Carneiro, <b>Nicholas J. Vogelzang</b> , Lauren Christine Harshman.	Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.	Abstract # 4579	Friday June 2
Alan Haruo Bryce, Yu-Hui Chen, Glenn Liu, Michael Anthony Carducci, David Frazier Jarrard, Jorge A. Garcia, Robert Dreicer, Maha Hussain, Mario A. Eisenberger, Manish Kohli, Noah M. Hahn, Elizabeth R. Plimack, <b>Nicholas J. Vogelzang</b> , Joel Picus, Robert S. DiPaola, Lauren Christine Harshman, Christopher Sweeney.	Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial.	Abstract # 5046	Friday June 2
Yves Fradet, Joaquim Bellmunt, Ronald De Wit, David J. Vaughn, Jae-Lyun Lee, Lawrence Fong, <b>Nicholas J. Vogelzang</b> , Miguel A. Climent, Daniel Peter Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stephane Culine, Cora N. Sternberg, Kijoeng Nam, Tara L. Frenkl, Rodolfo F. Perini, Dean F. Bajorin.	Pembrolizumab (pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.	Abstract # 4521	Friday June 2

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

Poster Presentations			
Authors	Title	Abstract #	Date
A. Oliver Sartor, Celestia S. Higano, Matthew R. Cooperberg, <b>Nicholas J. Vogelzang</b> , Shaker R. Dakhil, Christopher Michael Pieczonka, Jeff Vacirca, Raoul S Concepcion, Ronald F Tutrone, Luke T. Nordquist, Carl A Olsson, David F. Penson, <b>Ian Schnadig</b> , James L. Bailen, Bryan Mehlhaff, Nancy N. Chang, Nadeem Anwar Sheikh, Bruce Brown, Andrew J. Armstrong.	Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.	Abstract # 5041	Friday June 2
Mariaelena Pierobon, <b>Nicholas J. Robert</b> , Donald W. Northfelt, Mohammad Jahanzeb, Shukmei Wong, K. Alex Hodge, Jessica Aldrich, David W. Craig, Lance A. Liotta, Julia Dianne Wulfkuhle, Rosa Isela Gallagher, David Arguello, Amber Conrad, Ariane C. Kemkes, David M. Loesch, Linda Vocila, Bryant Dunetz, John D. Carpten, Emanuel Petricoin, Stephen Patrick Anthony.	Multi-Omic Profiling (MOP) of metastatic lesions to guide treatment selection: the Side Out 2 trial experience.	Abstract # 1077	Friday June 2
Cristina Gasparetto, <b>Robert M. Rifkin</b> , Howard R. Terebelo, Kathleen Toomey, Brian G. Durie, James W. Hardin, Sundar Jagannath, Lynn I. Wagner, Mohit Narang, Sikander Ailawadhi, E. Dawn Flick, Stanley Kotey, Shankar Srinivasan, Amani Kitali, Amit Agarwal, Rafat Abonour.	Predictors of long-term survival in newly diagnosed multiple myeloma (NDMM) patients (pts) enrolled in the Connect MM registry.	USOR Study # 9141 Abstract # 8037	Monday June 4
Sundar Jagannath, <b>Robert M. Rifkin</b> , Cristina Gasparetto, Kathleen Toomey, Brian G. Durie, James W. Hardin, Howard R. Terebelo, Lynn I. Wagner, Mohit Narang, Sikander Ailawadhi, Shankar Srinivasan, Ahmed YoussefAgha, Brian Ung, Amani Kitali, E. Dawn Flick, Amit Agarwal, Rafat Abonour.	Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry.	USOR Study # 9141 Abstract # 8041	Monday June 4
Jonathan W. Friedberg, Andres Forero-Torres, Beata Holkova, <b>Jerome H. Goldschmidt</b> , Ralph V. Boccia, Rodolfo Bordon, <b>Vivian Jean M. Cline, Dipti Patel-Donnelly, Patrick J. Flynn</b> , Gregg A. Olsen, Robert W. Chen, Faith Galderisi, Yinghui Wang, <b>Jeff Porter Sharman, Christopher A. Yasen</b> .	Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.	USOR Study # 11282 Abstract # 7542	Monday June 4
Vicky Makker, Drew W. Rasco, <b>Nicholas J. Vogelzang, Mark Messing</b> , Marcia S. Brose, <b>Allen Lee Cohn</b> , Carol Aghajanian, Daniel E. Stepan, Corina E. Dutcus, Emmett V. Schmidt, Matthew Guo, Pallavi Sachdev, Robert Charles Shumaker, Matthew H. Taylor.	Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results.	USOR Study # 15180 Abstract # 5596	Monday June 4
Herve Tilly, Christopher Flowers, Jonathan W. Friedberg, Charles Herbaux, Franck Morschhauser, Laurie Helen Sehn, <b>Jeff Porter Sharman</b> , Marek Trnėný, Lijia Wang, Calvin Lee, Gilles A. Salles.	A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).	USOR Study # 17050 Abstract # TPS7589	Monday June 4
Amrita Y. Krishnan, Nina Shah, <b>Alexander I. Spira</b> , Jonathan L. Kaufman, Ruben Niesvizky, Nirav Niranjani Shah, <b>John M. Burke</b> , Leslie Popplewell, Thomas G. Martin, Julee Cheung, Shannon L. Matheny, John Paul Leonard, Arturo Molina.	A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.	USOR Study # 17205 Abstract # TPS7586	Monday June 4
Amir Tahmasb Fathi, William Bruce Donnellan, Roger M. Lyons, Michael B. Maris, Tae Min Kim, Won Seog Kim, Gary J. Schiller, Camille N. Abboud, Martha Lucia Arellano, Elizabeth H. Cull, Karen W. L. Yee, Danielle Michelle Townsley, Fujun Wang, John G. Bothos, Nai-Shun Yao, Gilles A. Salles.	A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.	Abstract # TPS2603	Monday June 4

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

Poster Presentations			
Authors	Title	Abstract #	Date
Daniel A. Vaena, Jorge Chaves, <b>Nicholas J. Vogelzang</b> , Marc Ryan Matrana, A. Eli Gabayan, Matthew John Riese, Daniel C. Cho, Mary Ann Tagliaferri, Jonathan Zalevsky, Sunny Xie, Ute Hoch, AHSAN NAQI RIZWAN, Sandra Aung, Michael Imperiale, James K. Schwarz.	PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.	Abstract # TPS3115	Monday June 4
Anne S. Tsao, Jieling Miao, Ignacio Ivan Wistuba, <b>Nicholas J. Vogelzang</b> , John Heymach, Frank V. Fossella, Charles Lu, Mario R. Velasco, Brandy Box-Noriega, James Gilbert Hueftle, Shirish M. Gadgeel, Mary Weber Redman, David R. Gandara, Karen Kelly.	SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemo-naïve patients with malignant pleural mesothelioma.	Abstract # 8514	Monday June 4
Bryone J. Kuss, Matthew Steven Davids, Peter Hillmen, <b>James H. Essell</b> , Carol Moreno, Nicole Lamanna, Zsolt Nagy, Constantine Si Lun Tam, Stephan Stilgenbauer, Ulrich Jäger, Paolo Ghia, Julio Delgado, Ngocdiep T. Le, Brenda Jeglinski, Marco Montillo.	The efficacy of duvelisib monotherapy following disease progression on ofatumumab monotherapy in patients with relapsed/refractory CLL or SLL in the DUO crossover extension study.	Abstract # 7533	Monday June 4

Publications		
Authors	Title	Abstract #
<b>Donald A. Richards</b> , Maen A. Hussein, Steven L. McCune, <b>Brian Kent Ulrich</b> , Bijoy PanKaj Telivala, Marc Monte, Mark D. Danese, Michelle L. Gleeson, Deborah P. Lubeck, Jenine Sanzari, John R. Penrod, Yong Yuan, Pranav Abraham, Beata Korytowsky, Lee Steven Schwartzberg.	What is the benefit from second- and third-line (2L and 3L) therapy for extensive disease small cell lung cancer (ED-SCLC)? A prospective study of patterns, discontinuation, and survival in US community practices.	USOR Study # 13172 Abstract # e20567
Elizabeth Ruth Plummer, Natalie Cook, Hendrik-Tobias Arkenau, <b>Jason M. Melear</b> , Charles H. Redfern, <b>Alexander I. Spira</b> , <b>Ki Y. Chung</b> , Geoffrey Shapiro, Tufia C. Haddad, Suresh S. Ramalingam, Robert Wesolowski, Thomas Goddemeier, Martin H. Falk, Emma Dean.	Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).	USOR Study # 15215 Abstract # e21048
Sharad A. Ghamande, Guilherme Cantuaria, Anand P. Jillella, Vamsi Kota, Andrew Emmons Green, William Richards, <b>James J Burke</b> , Howard A. Zaren, Mark A. Taylor, Sreekanth Reddy, Melissa S. Dillmon, Andrew William Pippas, Frederick M. Schnell, Jayanthi Srinivasiah, Colleen H. McDonough, Joni Short, Geri Whitaker, Aprille Belgrave, Nancy M. Paris.	A collaborative pilot model among Georgia oncologists to strengthen clinical trial enrollment and promote equity of care for minorities.	Abstract # e18651
<b>Nicholas J. Vogelzang</b> , Mohamed Azab, Yen Cao, Subhikshya Tiwari, Mohamad Mubder.	Cell free (cf) DNA as a tumor marker in transitional cell cancer (TCC): Monitoring response to checkpoint inhibitor (CPI) therapy.	Abstract # e16522
Mohamed Azab, Yen Cao, Subhikshya Tiwari, Mohamad Mubder, Chad L Cross, <b>Nicholas J. Vogelzang</b> .	Cell free (cf)DNA as a tumor marker in transitional cell carcinoma (TCC).	Abstract # e16514
Celestia S. Higano, Andrew J. Armstrong, A. Oliver Sartor, <b>Nicholas J. Vogelzang</b> , Philip W. Kantoff, David G. McLeod, Christopher Michael Pieczonka, David F. Penson, Neal D. Shore, Jeffrey L. Vacirca, Raoul S Concepcion, Ronald F Tutrone, Luke T. Nordquist, David I. Quinn, Vahan Kassabian, Mark C. Scholz, Robert C. Tyler, Nancy N. Chang, Bruce Brown, Matthew R. Cooperberg.	Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry.	Abstract # e17018
Yen Cao, Mohamed Azab, Subhikshya Tiwari, Mohamad Mubder, <b>Nicholas J. Vogelzang</b> .	cFDNA characteristics in transitional cell carcinoma (TCC) patients who achieved complete response to checkpoint inhibitors (CPI).	Abstract # e16589
Ilana Schlam, Garima Gupta, James H. Essell.	Self-reported adherence to lenalidomide as maintenance therapy for multiple myeloma after autologous stem cell transplantation.	Abstract # e20046

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

HEOR - Poster Presentations			
Authors	Title	Abstract #	Date
<b>Gurjyot K. Doshi</b> , Abhijeet Bhanegaonkar, Murtuza Bharmal, Hemant Phatak, <b>Marley Boyd</b> , <b>Kathleen M Aguilar</b> , Mairead Kearney.	SPEAR-bladder (study informing treatment pathway decision in bladder cancer): First- through third-line time to treatment failure in the US.	<b>HEOR Study</b> Abstract # 4544	Friday June 2

HEOR - Publication		
Authors	Title	Abstract #
<b>C. Lance Cowey</b> , Sameer R. Ghatge, <b>Whitney C. Rhodes</b> , Thomas Wilson, Briana Ndife, <b>Janet L. Espirito</b> , Rohit Borker, <b>Jennifer R. Frytak</b> , Antonio Reis Nakasato, <b>Nicholas J. Robert</b> .	Adjuvant therapy utilization among stage III melanoma patients.	<b>HEOR Study</b> Abstract # e21574

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

# **ADDENDUM**

<b>Additional Presentations</b>				
Authors / Participants	Title	Type	Date/Time	Location
Debra A. Patt, MD, MPH, MBA - Chair	Understanding Utilization Management-Policy Background: Forms of Utilization Management From a Clinician Perspective	Education Session	Fri, Jun 01, 4:30 - 5:45 p.m.	S504
J. Russell Hoverman, MD, PhD - Speaker	Interpreting Practice Reports on Utilization and Using the Reports to Improve Practice Efficiencies	Education Session	Fri, Jun 01, 4:30 - 5:45 p.m.	S504
Neelima Denduluri, MD - Speaker	Tailored Therapy for Early-Stage HER2+ Breast Cancer	Education Session	Sat, Jun 02, 4:45 - 6:00 p.m.	Hall D1
Debra Patt, MD	Coffee Talk With ASCO's Female Leaders	Education Session	Sunday, June 3, 2018	S502
Alexander I. Spira, MD, PhD, FACP	The Impact of Immunotherapy On A Community Practice	Education Session	May 31, 2018 12:30 p.m.	S100bc
Authors / Participants	Title	Type	Date/Time	Number
<b>Robert M. Jotte</b> , Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodriguez Abreu, Maen A. Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Carlos Silva, Vilma Graupner, Shawn Sun, Ray S Lin, Claudia Kelsch, Marcin Kowanetz, Tien Hoang, Alan Sandler, Mark A. Socinski; Rocky Mountain Cancer Centers, Denver, CO; Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy; Sumy State University, Sumy Regional Clinical Oncology Center, Sumy, Ukraine; Moscow City Oncology Hospital #62, Moscow, Russian Federation; Department of Medical	IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.	Oral Abstract #LBA9000	Monday, June 4th me	USOR# 15014



<p>Oncology, Gran Canaria University Hospital, Las Palmas De Gran Canaria, Spain; Florida Cancer Specialists, Tavares, FL; National University Hospital / Cancer Science Institute, Singapore, Singapore; William Osler Health System, Toronto, ON, Canada; National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Fundação Pio XII Institution - Cancer Hospital of Barretos, Barretos, Brazil; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Genentech, Inc., South San Francisco, CA; Florida Hospital Cancer Institute, Orlando, FL</p>				
<p>Mark A. Socinski, <b>Robert M. Jotte</b>, Federico Cappuzzo, Francisco Jorquera Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodriguez-Abreu, Denis Moro-Sibilot, Christian A. Thomas, Fabrice Barlesi, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yijing Shen, Marcin Kowanetz, Ariel Lopez-Chavez, Alan Sandler, Martin Reck; Florida Hospital Cancer Institute, Orlando, FL; Rocky Mountain Cancer Centers, Denver, CO; AUSL Romagna, Ravenna, Italy; Instituto Nacional del Torax, Santiago, Chile; Moscow City Oncology Hospital #62, Moscow, Russian Federation; Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan; Hospital Universitavio Insular De Gran Canaria, Las Palmas,</p>	<p>Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.</p>	<p>Oral Abstract #9002</p>	<p>Monday, June 4th</p>	<p>USOR# 15013</p>

<p>Spain; Centre Hospitalier Universitaire de Grenoble, Grenoble, France; New England Cancer Specialists, Scarborough, ME; Hospital Nord Service Oncologie, Marseille, France; Allegheny Health Network Cancer Institute, Pittsburgh, PA; Genentech, Inc., South San Francisco, CA; Genentech, Inc, South San Francisco, CA; LungenClinic Grosshansdorf, German Center for Lung Research, Grosshansdorf, Germany</p>				
--	--	--	--	--

***Learn More:***

Online: [usoncology.com/research](http://usoncology.com/research)

Email: [researchopportunities@mckesson.com](mailto:researchopportunities@mckesson.com)

Phone: (281) 863-1000

---